Rebinyn Email Program




Brand: Rebinyn (coagulation factor IX (recombinant), GlycoPEGylated), Intravenous Infusion
Parent Company: Novo Nordisk
Drug Type: Prescription
Drug Category: Hematology
Campaign: Coming Soon
Targeting: HCPs
Patient Website: https://www.rebinyn.com/
HCP Website: https://www.rebinynpro.com

Email 1, subject line 1: A new treatment option for your patients

Sent on: Nov 11, 2017 at 10am EST

Same email, resent:

Email 1, subject line 2: FDA Approved for 2018: Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated)

Sent On: Jan 21, 2018 at 4pm EST

 

Email 2 subject line: Now available: Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated)

Sent on: Feb 6, 2018 and Feb 11, 2018

 

Email 3 subject line: Now available: Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated)

Sent on: Feb 26, 2018 and Mar 5, 2018

 

Email 4 subject line: An intro to Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated)

Sent on: Apr 3, 2018 and Apr 9, 2018